These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 26364372)

  • 1. [Clostridium difficile infection - an update].
    von Ameln-Mayerhofer A
    Med Monatsschr Pharm; 2015 Jun; 38(6):211-8; quiz 219-20. PubMed ID: 26364372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Best strategies in recurrent or persistent Clostridium difficile infection.
    Cocanour CS
    Surg Infect (Larchmt); 2011 Jun; 12(3):235-9. PubMed ID: 21767157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clostridium difficile infection in older adults: a review and update on its management.
    Kee VR
    Am J Geriatr Pharmacother; 2012 Feb; 10(1):14-24. PubMed ID: 22260856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnosis and management of Clostridium difficile infection.
    Dupont HL
    Clin Gastroenterol Hepatol; 2013 Oct; 11(10):1216-23; quiz e73. PubMed ID: 23542332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful treatment of simulated Clostridium difficile infection in a human gut model by fidaxomicin first line and after vancomycin or metronidazole failure.
    Chilton CH; Crowther GS; Freeman J; Todhunter SL; Nicholson S; Longshaw CM; Wilcox MH
    J Antimicrob Chemother; 2014 Feb; 69(2):451-62. PubMed ID: 24003182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnosis and management of Clostridium difficile infection.
    Korman TM
    Semin Respir Crit Care Med; 2015 Feb; 36(1):31-43. PubMed ID: 25643269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fidaxomicin (OPT-80) for the treatment of Clostridium difficile infection.
    Miller M
    Expert Opin Pharmacother; 2010 Jun; 11(9):1569-78. PubMed ID: 20446864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection.
    Debast SB; Bauer MP; Kuijper EJ;
    Clin Microbiol Infect; 2014 Mar; 20 Suppl 2():1-26. PubMed ID: 24118601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clostridium difficile infection: an update on epidemiology, risk factors, and therapeutic options.
    Lo Vecchio A; Zacur GM
    Curr Opin Gastroenterol; 2012 Jan; 28(1):1-9. PubMed ID: 22134217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of vancomycin dose on treatment outcomes in severe Clostridium difficile infection.
    Lam SW; Bass SN; Neuner EA; Bauer SR
    Int J Antimicrob Agents; 2013 Dec; 42(6):553-8. PubMed ID: 24103633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clostridium difficile infection in the "oldest" old: clinical outcomes in patients aged 80 and older.
    Cober ED; Malani PN
    J Am Geriatr Soc; 2009 Apr; 57(4):659-62. PubMed ID: 19392957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of fidaxomicin for the treatment of Clostridium difficile infection.
    Juang P; Hardesty JS
    J Pharm Pract; 2013 Oct; 26(5):491-7. PubMed ID: 24064437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of treatment outcomes with vancomycin alone versus combination therapy in severe Clostridium difficile infection.
    Bass SN; Bauer SR; Neuner EA; Lam SW
    J Hosp Infect; 2013 Sep; 85(1):22-7. PubMed ID: 23876778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current and emerging management options for Clostridium difficile infection: what is the role of fidaxomicin?
    Cornely OA
    Clin Microbiol Infect; 2012 Dec; 18 Suppl 6():28-35. PubMed ID: 23121552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fidaxomicin for the treatment of Clostridium difficile infections.
    Whitman CB; Czosnowski QA
    Ann Pharmacother; 2012 Feb; 46(2):219-28. PubMed ID: 22318930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clostridium difficile infection: New insights into therapeutic options.
    Kachrimanidou M; Sarmourli T; Skoura L; Metallidis S; Malisiovas N
    Crit Rev Microbiol; 2016 Sep; 42(5):773-9. PubMed ID: 25955884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of continued antibacterial therapy after diagnosis of hospital-onset Clostridium difficile infection: implications for antimicrobial stewardship.
    Harpe SE; Inocencio TJ; Pakyz AL; Oinonen MJ; Polk RE
    Pharmacotherapy; 2012 Aug; 32(8):744-54. PubMed ID: 23307522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Recurrent Clostridium difficile infections: the importance of the intestinal microbiota].
    Zanella Terrier MC; Frossard JL; Simonet ML
    Rev Med Suisse; 2013 Oct; 9(402):1898, 1900-4. PubMed ID: 24298714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea.
    Tart SB
    J Pharm Pract; 2013 Oct; 26(5):488-90. PubMed ID: 23940121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rethinking Strategies to Select Antibiotic Therapy in Clostridium difficile infection.
    Chopra T; Goldstein EJ; Gorbach SL
    Pharmacotherapy; 2016 Dec; 36(12):1281-1289. PubMed ID: 27862113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.